Friday, October 5, 2012

Theralase Commences Equity Financing

TORONTO, ONTARIO-- Oct. 4, 2011 - Theralase Technologies Inc. (TSX-V:TLT) announced today that it has commenced raising funds from accredited investors in a non-brokered private placement (the "Private Placement") of up to 2,000,000 units (the "Units") at a price of CND $0.25 per Unit for gross proceeds of up to CDN $500,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non- transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to purchase one additional common share (a "Warrant Share") in the capital of the Company for 1 year after closing at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month holding period, commencing upon closing.

The company intends to utilize the proceeds of the Private Placement to provide additional working capital to further develop the Company's prospects in a number of areas, specifically:

·       Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network
·       Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of cancers, bacteria and viruses
·       TLC-1000 therapeutic medical laser USA sales and marketing expansion
·       TLC-2000 therapeutic medical biofeedback laser commercialization

About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit, regulatory filings may be viewed by visiting

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin-White,                                                                                  
President and CEO                                                                                            
416-447-8455 ext. 225                                                                                      

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224                                                                                

Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262


  1. Acupuncture in Toronto: As the most expensive form of automobile ground transportation, limousines are culturally associated with extreme wealth or power and are commonly cited as examples of conspicuous consumption. Among the less wealthy, limousines are often hired during special events (most commonly weddings, proms, and bachelor parties).Foot Massage Toronto

  2. When turnkey rental business is strong, we sometimes forget about being frugal, but we all remember the “bad days” of the appraisal recession in the mid-1990s. rental properties

  3. eToro is the #1 forex trading platform for rookie and advanced traders.